RxDoctor Payments Data

Thanh Do, MD

Internal Medicine · Houston, TXNPI 1083663033

Payments from drug & device makers

$1,811in general payments, 2019–2025

Across 69 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$446
  • AbbVie$293
  • Abbott$227
  • Bayer$192
  • Novo Nordisk$181
  • Gilead$122
  • plus $350 from 10 others

What the payments were for

  • Food & beverage$1,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,811 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,283
Medicare patients
47
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol28$40,199
OzempicSemaglutide21$28,223
JardianceEmpagliflozin17$19,150
TrulicityDulaglutide13$16,074
VascepaIcosapent Ethyl19$12,046
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,036
Diclofenac Sodium81$2,800
Albuterol Sulfate HfaAlbuterol Sulfate112$2,294
Colchicine15$2,012
Omega-3 Acid Ethyl Esters47$1,160
Ventolin HfaAlbuterol Sulfate15$1,116
Atorvastatin Calcium183$884
Celecoxib11$766
Fluticasone Propionate93$748
Pregabalin21$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$446$40,19928 claims
Novo NordiskOzempic$181$28,22321 claims
Lilly USA, LLCTrulicity$76$16,07413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →